May 5th, 2025 | 07:00 CEST
NEW PRICE TARGET: RENK, Novo Nordisk, and takeover candidate BioNxt Solutions
Analysts are raising their price target for RENK shares significantly. However, they appear to be trailing the current share price. Things will likely get exciting at RENK on May 15, when fresh figures and, hopefully, a well-filled order book will be reported. BioNxt Solutions shares are currently of interest. Clinical trials are about to begin on the development of the leading product for the easier treatment of multiple sclerosis. The stock is cheap and seen as a hot takeover candidate - perhaps for Novo Nordisk? With simplified administration, the Danes could further accelerate sales of Ozempic and potentially reduce costs. The stock is working on a bottom, and analysts recommend it as a "Buy".
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
RENK AG O.N. | DE000RENK730 , NOVO NORDISK A/S | DK0062498333 , Bionxt Solutions Inc. | CA0909741062
Table of contents:
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
BioNxt Solutions: Bioequivalence study in less than 30 days
The stock of biotech gem BioNxt Solutions could soon end its consolidation at around EUR 0.30 and climb back toward its high for the year at EUR 0.40. This is because important results are pending in the development of its lead product, BNT23001. With BNT23001, BioNxt aims to improve therapeutic outcomes for patients with chronic diseases such as multiple sclerosis (MS).
To this end, BioNxt is developing an orally dissolvable film formulation of cladribine for the treatment of MS. Preclinical studies have already demonstrated numerous advantages over existing therapies based on internal research data and third-party evaluations. BioNxt has now announced that it has acquired the active pharmaceutical ingredient cladribine to complete the technology transfer process with Gen-Plus, the European Contract Research and Development Organization (CRDO) based in Munich. BioNxt expects the bioequivalence study to take less than 30 days.
Shareholders can, therefore, expect a flurry of news in the coming weeks. If the clinical trial of BNT23001 is successful, BioNxt, with a market capitalization of less than EUR 50 million, would be a real bargain and an interesting takeover candidate. This is because administration via orally dissolvable films will likely offer advantages for many therapies and make a takeover of BioNxt attractive to pharmaceutical companies.
Another argument in favor of a takeover is BioNxt's expansion into another billion-dollar market: life-prolonging and anti-aging products. BioNxt develops orally dissolvable films and gastro-resistant tablets for active pharmaceutical ingredients that have been shown to be beneficial in the early stages of slowing ovarian aging, prolonging fertility, and promoting healthier aging. According to Statista, this industry is expected to generate USD 93 billion in revenue by 2027.
Novo Nordisk: Buy shares now?
One potential buyer for BioNxt could be Novo Nordisk. The Danish company is researching simpler administration options for its blockbuster drug Ozempic, among other things. Although taking the drug via injection is anything but convenient, Novo is still unable to meet demand. Numerous celebrities are providing free advertising. Most recently, Bild newspaper reported that Oliver Pocher lost around 14 kilograms with Ozempic. As an orally dissolvable film or tablet, it would not only be much easier to take but also likely cheaper to produce.
The fact that expectations for Ozempic's billion-dollar sales were somewhat too high is reflected in the performance of Novo Nordisk's share price this year. Since its high in mid-December at over EUR 100, the share has lost around 40% of its value and is currently bottoming out. UBS recently confirmed its "Buy" recommendation for Novo Nordisk shares. The price target is DKK 750.
RENK: Target price rises
Analysts also recommend buying RENK shares. However, they are tending to lag behind the rising share price. There was an example of this last week. Jefferies initially confirmed its "Buy" recommendation with a target price of EUR 44. However, the share price was already above EUR 47 at that point. The analysts also noticed that the rating, target price, and current price did not match. On Friday, they raised their target price for the shares of the manufacturer of the Leopard 2 battle tank to EUR 60. The reason for this is that the estimates for 2028 have now also been included in the study. Analysts expect RENK to publish solid figures on May 15 and growth to accelerate significantly in the coming years.
According to marketscreener.com, the average price target for RENK shares is currently around EUR 50. The share is currently trading above EUR 54. Nevertheless, there are eight buy recommendations, and only three experts advise holding.
Like many defense stocks, RENK is currently riding the momentum wave. The stock is highly valued, but it has the potential to grow into this valuation. Investors can look forward to important news from BioNxt in the coming weeks. The stock should then end its consolidation phase. A takeover also becomes more likely with every positive announcement. BioNxt's technology could be useful for Novo Nordisk, among others. The euphoria surrounding Ozempic has faded on the stock market, which could indicate the end of the slump.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
